Navigation Links
Innovation in science
Date:4/15/2010

Results of a study presented today at the at the International Liver CongressTM 2010 reveals the effects of a new drug for the treatment of primary biliary cirrhosis, and shows further evaluation is necessary.

INT-747 is a novel derivative of a human bile acid CDCA (that binds to the farnesoid-X receptor). In patients with PBC, addition of INT-747 to UDCA resulted in a significant amelioration of liver enzymes compared to placebo.

PBC is a chronic disease that damages bile ducts. Bile can no longer flow and builds up in the liver instead, damaging the liver cells and causing inflammation and scarring. This eventually leads to cirrhosis.


'/>"/>

Contact: Isabelle Scali
media.easl2010@cohnwolfe.com
44-771-743-5103
European Association for the Study of the Liver
Source:Eurekalert

Page: 1

Related biology news :

1. IEEE-USA innovation forum will help prepare US tech leaders to prosper in a global marketplace
2. First IEEE-USA Innovation Forum coming to Washington area in November
3. OHSU turns innovations into commercial opportunities at record pace
4. Synaptics SecurePad(TM) Selected as CES Innovations 2008 Design and Engineering Award Honoree
5. United Water, in partnership with Stevens, wins Management Innovation Award
6. How will government spur technological innovation in the 21st century?
7. Sonic Innovations Celebrates 10-Year Anniversary
8. Brown opens institute for molecular and nanoscale innovation
9. Atmel Receives Frost & Sullivans Technology Innovation Award for FingerChip(R) Biometric Sensor
10. Watson-inspired innovation in research at Cold Spring Harbor Laboratory
11. New chemical radar among national security innovations in ACS podcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample ... the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
Breaking Biology Technology: